Format

Send to

Choose Destination
Cancer Cell. 2012 Mar 20;21(3):327-9. doi: 10.1016/j.ccr.2012.03.002.

Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?

Author information

1
Ontario Cancer Institute/Princess Margaret Hospital, University Health Network and University of Toronto, Canada.

Abstract

Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs.

PMID:
22439929
DOI:
10.1016/j.ccr.2012.03.002
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center